Following preclinical data demonstrating that treatment with the monoclonal BNT3A antibody ICT01 can activate unique antitumor γ9δ2 T cells and encourage their trafficking to tumors, a phase I/IIa, first-in-human clinical trial of the agent is under way. Early data show corresponding results in ICT01-treated patients.

©2021 American Association for Cancer Research.
2021
American Association for Cancer Research.
You do not currently have access to this content.